{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:06:53Z","timestamp":1789434413585,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["10\/IN.1\/B3012"],"award-info":[{"award-number":["10\/IN.1\/B3012"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["19\/FIP\/AI\/7490"],"award-info":[{"award-number":["19\/FIP\/AI\/7490"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["18\/RI\/5702"],"award-info":[{"award-number":["18\/RI\/5702"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jtha.2024.09.030","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T11:27:15Z","timestamp":1728991635000},"page":"531-545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Rivaroxaban, in combination with low-dose aspirin, is associated with a reduction in proinflammatory and prothrombotic circulating vesicle signatures in patients with cardiovascular disease"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7018-5325","authenticated-orcid":false,"given":"Luisa","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aideen","family":"O\u2019Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wido","family":"Uhrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina B.","family":"Szklanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Hong-Minh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Wynne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Zivny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Lima Passos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Kevane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se\u00e1n","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fionnuala","family":"N\u00ed \u00c1inle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia B.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.09.030_bib1","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics - 2018 update: a report from the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.09.030_bib2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/hrt.60.6.459","article-title":"Morphology of the endothelium over atherosclerotic plaques in human coronary arteries","volume":"60","author":"Davies","year":"1988","journal-title":"Br Heart J"},{"key":"10.1016\/j.jtha.2024.09.030_bib3","article-title":"Primary prevention of cardiovascular disease: a review of contemporary guidance and literature","volume":"6","author":"Stewart","year":"2017","journal-title":"JRSM Cardiovasc Dis"},{"key":"10.1016\/j.jtha.2024.09.030_bib4","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.09.030_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.09.030_bib6","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.09.030_bib7","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1055\/s-0038-1636530","article-title":"Rivaroxaban: a new treatment paradigm in the setting of vascular protection?","volume":"118","author":"Bauersachs","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.09.030_bib8","doi-asserted-by":"crossref","first-page":"915","DOI":"10.5551\/jat.48405","article-title":"Rivaroxaban suppresses the progression of ischemic cardiomyopathy in a murine model of diet-induced myocardial infarction","volume":"26","author":"Liu","year":"2019","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"10.1016\/j.jtha.2024.09.030_bib9","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1253\/circj.CJ-20-1006","article-title":"Activated factor X signaling pathway via protease-activated receptor 2 is a novel therapeutic target for preventing atrial fibrillation","volume":"85","author":"Matsuura","year":"2021","journal-title":"Circ J"},{"key":"10.1016\/j.jtha.2024.09.030_bib10","first-page":"2335","article-title":"Direct factor Xa inhibition attenuates acute lung injury progression via modulation of the PAR-2\/NF-\u03baB signaling pathway","volume":"10","author":"Shi","year":"2018","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.jtha.2024.09.030_bib11","first-page":"1619","article-title":"Protective effect of rivaroxaban on arteriosclerosis obliterans in rats through modulation of the toll-like receptor 4\/NF-\u03baB signaling pathway","volume":"18","author":"Lou","year":"2019","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jtha.2024.09.030_bib12","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.09.030_bib13","article-title":"Platelet extracellular vesicles induce a pro-inflammatory smooth muscle cell phenotype","volume":"6","author":"Vajen","year":"2017","journal-title":"J\u00a0Extracell Vesicles"},{"key":"10.1016\/j.jtha.2024.09.030_bib14","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0002-8703(03)00103-0","article-title":"High levels of circulating endothelial microparticles in patients with acute coronary syndromes","volume":"145","author":"Bernal-Mizrachi","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2024.09.030_bib15","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1055\/s-0030-1267042","article-title":"Platelet- and megakaryocyte-derived microparticles","volume":"36","author":"Flaumenhaft","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.09.030_bib16","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/09537104.2016.1190008","article-title":"Effects of antiplatelet therapy on platelet extracellular vesicle release and procoagulant activity in health and in cardiovascular disease","volume":"27","author":"Connor","year":"2016","journal-title":"Platelets"},{"key":"10.1016\/j.jtha.2024.09.030_bib17","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1096\/fj.201500150R","article-title":"Human plasma platelet-derived exosomes: effects of aspirin","volume":"30","author":"Goetzl","year":"2016","journal-title":"FASEB J"},{"key":"10.1016\/j.jtha.2024.09.030_bib18","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1111\/jth.15434","article-title":"Non-valvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro-inflammatory protein signatures","volume":"19","author":"Weiss","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.09.030_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1975056","article-title":"Endothelial microvesicles and soluble markers of endothelial injury in critically ill newborns","volume":"2018","author":"V\u00edtkov\u00e1","year":"2018","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jtha.2024.09.030_bib20","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/ehjcvp\/pvac023","article-title":"Long-term treatment with the combination of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: outcomes during the open label extension of the COMPASS trial","volume":"8","author":"Eikelboom","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jtha.2024.09.030_bib21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/jth.12554","article-title":"Extracellular vesicles from blood plasma: determination of their morphology, size, phenotype and concentration","volume":"12","author":"Arraud","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.09.030_bib22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14779072.2020.1806712","article-title":"Aspirin and low-dose rivaroxaban\u2013the dual pathway concept in patients with stable atherosclerotic disease: a comprehensive review","volume":"18","author":"Parascandolo","year":"2020","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jtha.2024.09.030_bib23","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"J\u00a0Extracell Vesicles"},{"key":"10.1016\/j.jtha.2024.09.030_bib24","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines","volume":"7","author":"Th\u00e9ry","year":"2018","journal-title":"J\u00a0Extracell Vesicles"},{"key":"10.1016\/j.jtha.2024.09.030_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jtha.2024.09.030_bib26","article-title":"Formation of a protein corona on the surface of extracellular vesicles in blood plasma","volume":"10","author":"T\u00f3th","year":"2021","journal-title":"J\u00a0Extracell Vesicles"},{"key":"10.1016\/j.jtha.2024.09.030_bib27","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/blood-2011-03-343061","article-title":"Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4","volume":"118","author":"Semeraro","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.09.030_bib28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1161\/CIRCULATIONAHA.120.046677","article-title":"Endotoxinemia accelerates atherosclerosis through electrostatic charge-mediated monocyte adhesion","volume":"143","author":"Schumski","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.09.030_bib29","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2017013573","article-title":"Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction","volume":"2","author":"Borst","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.09.030_bib30","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists' (ATT) Collaboration","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.09.030_bib31","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/CIRCRESAHA.118.313141","article-title":"Synergy of dual pathway inhibition in chronic cardiovascular disease","volume":"124","author":"Coppens","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.jtha.2024.09.030_bib32","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/432080","article-title":"Evaluation of plaque stability of advanced atherosclerotic lesions in Apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban","volume":"2011","author":"Zhou","year":"2011","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jtha.2024.09.030_bib33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11239-020-02126-3","article-title":"Thrombin Generation and other hemostatic parameters in patients with atrial fibrillation in use of warfarin or rivaroxaban","volume":"51","author":"Duarte","year":"2021","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2024.09.030_bib34","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1055\/s-0037-1613853","article-title":"Platelet vesiculation in angina patients treated with coronary angioplasty","volume":"83","author":"Combes","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.09.030_bib35","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1160\/TH10-12-0810","article-title":"Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease","volume":"106","author":"Mobarrez","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.09.030_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/10760296211019465","article-title":"Increased levels of platelets and endothelial-derived microparticles in patients with non-valvular atrial fibrillation during rivaroxaban therapy","volume":"27","author":"Lenart-Migdalska","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.09.030_bib37","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1139\/y11-013","article-title":"Acetylsalicylate reduces endothelial and platelet-derived microparticles in patients with coronary artery disease","volume":"89","author":"Bulut","year":"2011","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.jtha.2024.09.030_bib38","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00125-021-05562-9","article-title":"Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers","volume":"64","author":"Pistrosch","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.jtha.2024.09.030_bib39","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1164\/rccm.201206-1037OC","article-title":"Circulating histones are mediators of trauma-associated lung injury","volume":"187","author":"Abrams","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtha.2024.09.030_bib40","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3389\/fimmu.2018.01463","article-title":"LPS-challenged macrophages release microvesicles coated with histones","volume":"9","author":"Nair","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2024.09.030_bib41","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.4049\/jimmunol.1202733","article-title":"Histones activate the NLRP3 Inflammasome in Kupffer cells during sterile inflammatory liver injury","volume":"191","author":"Huang","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jtha.2024.09.030_bib42","doi-asserted-by":"crossref","first-page":"31309","DOI":"10.1073\/pnas.2013877117","article-title":"Retinol binding protein 4 primes the NLRP3 inflammasome by signaling through Toll-like receptors 2 and 4","volume":"117","author":"Moraes-Vieira","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2024.09.030_bib43","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.3390\/ijms22073601","article-title":"The role of circulating biomarkers in peripheral arterial disease","volume":"22","author":"Saenz-Pipaon","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtha.2024.09.030_bib44","doi-asserted-by":"crossref","first-page":"13257","DOI":"10.1074\/jbc.RA118.002428","article-title":"High-density lipoprotein inhibits serum amyloid A\u2013mediated reactive oxygen species generation and NLRP3 inflammasome activation","volume":"293","author":"Shridas","year":"2018","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.09.030_bib45","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1161\/CIRCULATIONAHA.113.002670","article-title":"Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis","volume":"128","author":"Boekholdt","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.09.030_bib46","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.7150\/thno.54004","article-title":"Exosome-inflammasome crosstalk and their roles in inflammatory responses","volume":"11","author":"Noonin","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.jtha.2024.09.030_bib47","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1161\/CIRCRESAHA.120.317219","article-title":"Different DOACs control inflammation in cardiac ischemia-reperfusion differently","volume":"128","author":"Gadi","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jtha.2024.09.030_bib48","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.09.030_bib49","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1055\/s-0040-1701206","article-title":"Effects of rivaroxaban on biomarkers of coagulation and inflammation: a post hoc analysis of the X-VeRT trial","volume":"4","author":"Kirchhof","year":"2020","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2024.09.030_bib50","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1161\/ATVBAHA.109.200451","article-title":"HABP2 is a novel regulator of vascular integrity","volume":"30","author":"Mambetsariev","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.09.030_bib51","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3390\/ijms20071762","article-title":"The cardioprotective signaling activity of activated protein C in heart failure and ischemic heart diseases","volume":"20","author":"Ren","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtha.2024.09.030_bib52","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood-2003-08-2804","article-title":"Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions","volume":"103","author":"Coppinger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.09.030_bib53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11239-007-0047-3","article-title":"Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease","volume":"25","author":"Serebruany","year":"2008","journal-title":"J\u00a0Thromb Thrombolysis"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624005798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624005798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:12:20Z","timestamp":1762549940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624005798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1538783624005798"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.09.030","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivaroxaban, in combination with low-dose aspirin, is associated with a reduction in proinflammatory and prothrombotic circulating vesicle signatures in patients with cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.09.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}